MedPath

Diltiazem

Generic Name
Diltiazem
Brand Names
Cardizem, Cartia, Matzim, Taztia, Tiadylt, Tiazac
Drug Type
Small Molecule
Chemical Formula
C22H26N2O4S
CAS Number
42399-41-7
Unique Ingredient Identifier
EE92BBP03H
Background

Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. Compared to dihydropyridine drugs, such as nifedipine, that preferentially act on vascular smooth muscle and verapamil that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle. Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation, atrial flutter. Apart from its main FDA-approved indications, diltiazem has also been used for numerous off-label indications, such as anal fissures (in topical formulations), migraine prophylaxis, pulmonary hypertension, and rest-related cramps in the lower extremities. Typically available in extended-release oral and intravenous formulations, diltiazem is marketed under various brand names with Cardizem and Tiazac being the most common ones.

Indication

Oral

Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.

Indicated for use to improve exercise tolerance in patients with chronic stable angina.

Indicated for the management of variant angina (Prinzmetal's angina).

Intravenous

Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.

Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.

Off-label

Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension, idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.

Associated Conditions
Angina Pectoris, Variant, Anginal Pain, Atrial Fibrillation, Atrial Flutter, Chronic Stable Angina Pectoris, Dilated Cardiomyopathies, Idiopathic, Fissure;Anal, Hypertension, Paroxysmal Supraventricular Tachycardia (PSVT), Proteinuria, Pulmonary Hypertension (PH), Leg cramps, Prophylaxis of migraine headaches

A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2016-01-12
Last Posted Date
2018-02-23
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT02653872
Locations
🇬🇧

Research Site, London, United Kingdom

Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2015-08-18
Last Posted Date
2018-07-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
14
Registration Number
NCT02526888
Locations
🇩🇪

CRS Clinical Research Services Kiel GmbH, Kiel, Germany

Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441

Phase 1
Terminated
Conditions
Healthy Subjects
Interventions
Drug: ACT-334441 2 mg
Drug: ACT-334441 4 mg
Drug: Placebo
First Posted Date
2015-06-24
Last Posted Date
2018-07-10
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
Target Recruit Count
10
Registration Number
NCT02479204
Locations
🇫🇷

BIOTRIAL, Rennes, France

A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2014-12-18
Last Posted Date
2016-09-16
Lead Sponsor
Pfizer
Target Recruit Count
22
Registration Number
NCT02319148
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block

Phase 1
Completed
Conditions
Pharmacokinetics
Pharmacodynamics
Drug-induced QT Prolongation
Interventions
First Posted Date
2014-12-04
Last Posted Date
2016-06-08
Lead Sponsor
Food and Drug Administration (FDA)
Target Recruit Count
22
Registration Number
NCT02308748

A Study of LY2623091 in Healthy Participants

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2014-11-24
Last Posted Date
2020-06-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
48
Registration Number
NCT02300259
Locations
🇺🇸

Covance Clinical Research Inc, Daytona Beach, Florida, United States

Treatment Of Chronic Anal Fissure

Not Applicable
Terminated
Conditions
Chronic Anal Fissure
Interventions
Other: Levorag Emulgel
First Posted Date
2014-06-06
Last Posted Date
2020-01-14
Lead Sponsor
Bispebjerg Hospital
Target Recruit Count
55
Registration Number
NCT02158013
Locations
🇩🇰

Department of Surgery P, Aarhus University Hospital, Aarhus, Denmark

🇩🇰

Digestive Disease Center, Bispebjerg Hospital, Copenhagen, Denmark

Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects

Phase 1
Completed
Conditions
CLARITHROMYCIN/DILTIAZEM [VA Drug Interaction]
Interventions
First Posted Date
2014-03-06
Last Posted Date
2014-04-14
Lead Sponsor
Ventrus Biosciences, Inc
Target Recruit Count
24
Registration Number
NCT02080780
Locations
🇺🇸

TKL Research, Paramus, New Jersey, United States

Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control

Phase 4
Conditions
Atrial Fibrillation
Atrial Flutter
Interventions
First Posted Date
2014-01-01
Last Posted Date
2017-08-09
Lead Sponsor
CAMC Health System
Target Recruit Count
150
Registration Number
NCT02025465
Locations
🇺🇸

Charleston Area Medical Center, Charleston, West Virginia, United States

A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate

Phase 1
Completed
Conditions
Healthy Volunteers
Pharmacologic Action
Interventions
Drug: Group 1 AZD3293
Drug: Group 2 AZD3293
Drug: Group 3 AZD3293
First Posted Date
2013-12-13
Last Posted Date
2014-04-28
Lead Sponsor
AstraZeneca
Target Recruit Count
56
Registration Number
NCT02010970
Locations
🇺🇸

Research Site, Cypress, California, United States

© Copyright 2025. All Rights Reserved by MedPath